Related Experiment Video

Updated: Jul 28, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer

R I Nicholson1, I R Hutcheson, M E Harper

  • 1Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, Wales. nicholsonri@cardiff.ac.uk

Annals of the New York Academy of Sciences
|July 4, 2002
PubMed

Insights

Growth factor networks interact with estrogen receptor signaling in breast cancer. Targeting epidermal growth factor receptor signaling may treat antihormone-resistant breast cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Estrogen receptor (ER) signaling is crucial for breast cancer growth.
  • Growth factor networks interact with ER signaling.
  • Antihormone therapies target ER but resistance is a clinical challenge.

Purpose of the Study:

  • To examine growth factor network modulation during endocrine therapy.
  • To investigate the role of epidermal growth factor receptor (EGFR) signaling in antihormone resistance.
  • To evaluate the potential of EGFR-targeted therapy for endocrine-resistant breast cancer.

Main Methods:

  • In vitro studies using breast cancer cell lines.
  • Analysis of clinical data.
  • Examination of EGFR signaling pathways in relation to ER status.

Main Results:

  • EGFR signaling is critical for antihormone-resistant breast cancer growth.
  • EGFR signaling can be maintained independently of ER.
  • The EGFR-selective tyrosine kinase inhibitor Iressa (ZD 1839) shows potential.

Conclusions:

  • EGFR signaling is a key mechanism in endocrine-resistant breast cancer.
  • Targeting EGFR may overcome or prevent antihormone resistance.
  • Iressa represents a promising therapeutic strategy for endocrine-resistant breast cancer.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.